Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 32nd Annual J.P. Morgan Healthcare Conference in San

  Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the
      32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA

PR Newswire

SAN FRANCISCO, Jan. 8, 2014

SAN FRANCISCO, Jan. 8, 2014 /PRNewswire/ --Nektar Therapeutics' (Nasdaq:
NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to
present at the upcoming 32^nd Annual J.P. Morgan Healthcare Conference in San
Francisco at the Westin St. Francis Hotel on Tuesday, January 14, 2014 at
10:00 a.m. Pacific time.

The presentation will be accessible via a Webcast through a link posted on the
Investor Relations, Events Calendar section of the Nektar website: This Webcast will be available for replay until
February 18, 2014.

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel
therapeutics based on its PEGylation and advanced polymer conjugation
technology platforms. Nektar has a robust R&D pipeline of potentially
high-value therapeutics in oncology, pain and other therapeutic areas. In the
area of pain, Nektar has an exclusive worldwide license agreement with
AstraZeneca for naloxegol (NKTR-118), an investigational drug candidate, which
has been filed for regulatory approvals in the U.S., Europe and Canada as a
once- daily, oral tablet for the treatment of opioid-induced constipation.
This agreement also includes NKTR-119, an earlier stage development program
that is a co-formulation of naloxegol and an opioid. NKTR-181, a novel
mu-opioid analgesic candidate for chronic pain conditions, has completed Phase
2 development in osteoarthritis patients with chronic knee pain. NKTR-192, a
novel mu-opioid analgesic in development to treat acute pain is in Phase 1
clinical development. In oncology, etirinotecan pegol (NKTR-102) is being
evaluated in a Phase 3 clinical study (the BEACON study) for the treatment of
metastatic breast cancer and is also in Phase 2 studies for the treatment of
ovarian, colorectal, lung and brain cancers. In anti-infectives, Amikacin
Inhale is in Phase 3 studies conducted by Bayer Healthcare as an adjunctive
treatment for intubated and mechanically ventilated patients with
Gram-negative pneumonia. Additional development-stage products that leverage
Nektar's proprietary technology platform include Baxter's BAX 855, a
longer-acting PEGylated rFVIII program, which is completing Phase 3 clinical

Nektar's technology has enabled eight approved products in the U.S. or Europe
through partnerships with leading biopharmaceutical companies, including UCB's
Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for
hepatitis C and Amgen's Neulasta® for neutropenia.

Nektar is headquartered in San Francisco, California, with additional
operations in Huntsville, Alabama and Hyderabad, India. Further information
about the company and its drug development programs and capabilities may be
found online at

CONTACT: Jennifer Ruddock/Nektar Therapeutics, (415) 482-5585

SOURCE Nektar Therapeutics

Press spacebar to pause and continue. Press esc to stop.